• PMH29 DRUG UTILIZATION PATTERNS AND COSTS AND TOTAL COSTS OF SCHIZOPHRENIA TREATMENT IN AN INSURED POPULATION

    Nov 1, 2005, 00:00

  • PCV1 COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION IN HUNGARY

    Nov 1, 2005, 00:00

  • PMH35 ARE INDIRECT COSTS MEASUREMENTS RELEVANT INA SCHIZOPHRENIC PATIENTS POPULATION? AN OVERVIEW OF A LONGITUDINAL STUDY IN FRANCE

    Nov 1, 2005, 00:00

  • PUK27 PSYCHOMETRIC VALIDATION OF THE UK ENGLISH INCONTINENCE-SPECIFIC QUALITY OF LIFE MEAURE (I-QOL)

    Nov 1, 2005, 00:00

  • PMH39 ARE QALYS SUITABLE FOR SCHIZOPHRENIA TRIALS?

    Nov 1, 2005, 00:00

  • PMC22 RELATIVE WEIGHTS ASSIGNED TO PHARMACY PROCEDURES- OPPS METHODS DESIGN AND CONCEPTS

    Nov 1, 2005, 00:00

  • DN1 ECONOMIC EVALUATIONOF SPECT-DATSCAN IN THE DIAGNOSIS OF PATIENTS WITH CLINICALLY UNCERTAIN PARKINSONISM IN ITALY

    Nov 1, 2005, 00:00

  • PSU7 “TECHNO-MARKERS” FOR THE ASSESSMENT OF HEALTH TECHNOLOGY UTILIZATION

    Nov 1, 2005, 00:00

  • PPN4 DIFFERENTIAL COSTS OF NEUROPHATIC PAIN (NEP) MEDICAL MANAGEMENT ACCORDING TO AETIOLOGY- RESULTS OF THE REC STUDY

    Nov 1, 2005, 00:00

  • PSN11 PREDICTORS OF HEALTH CARE OUTCOMES AND COSTS RELATED TO MEDICATION USE IN PATIENTS WITH ACNE IN THE UNITED STATES

    Nov 1, 2005, 00:00

  • PRS16 CHRONIC OBSTRUCTIVE PULMONARY DISEASE- A COMPARISON OF ESTIMATES OF HEALTH-RELATED UTILITY (EQ5D) FROM SF36 DATA ALONE, THE SF36 PLUS LUNG FUNCTION DATA, AND THE SF36 PLUS THE ST. GEORGE'S RESPIRATORY QUESTIONNAIRE PLUS LUNG FUNCTION ...

    Nov 1, 2005, 00:00

  • PMC26 DEVELOPMENT AND VALIDATION OF A DUTCH VERSION OF THE LONDON HANDICAP SCALE

    Nov 1, 2005, 00:00

  • PST1 PREDICTORS OF STROKE RISK ASSOCIATED WITH ATRIAL FIBRILLATION- RESULTS FROM A LARGE COMMERCIALLY INSURED US POPULATION

    Nov 1, 2005, 00:00

  • PDB49 PATTERNS OF BLOOD GLUCOSE MONITORING IN RELATION TO GLYCAEMIC CONTROL AMONG PATIENTS WITH TYPE-2 DIABETES IN THE UK

    Nov 1, 2005, 00:00

  • PCV54 CARDIOVASCULAR RISK CONTROL IN HYPERTENSION AND/OR DYSLIPIDEMIA IN PRIMARY CARE

    Nov 1, 2005, 00:00

  • PEY5 COMPARING EFFICACY OF PROSTAGLANDIN ANALOGUES FOR CONTROLLING INTRA-OCULAR PRESSURE (IOP)- RESULTS OF A META-ANALYSIS

    Nov 1, 2005, 00:00

  • PCN51 DEVELOPMENT OF A NEW SCALE TO ASSESS PATIENT PERCEPTIONS OF CANCER-RELATED FATIGUE- THE PERFORM PROJECT

    Nov 1, 2005, 00:00

  • PCV92 HEALTH RELATED QUALITY OF LIFE (QOL) IN PATIENTS RECEIVING VITAMIN K ANTAGONISTS (VKA)- A STUDY USING EQ-5D QUESTIONNAIRE

    Nov 1, 2005, 00:00

  • PCV65 PHARMACOECONOMIC ANALYSIS OF 160MG VALSARTAN VERSUS LOSARTAN AND TELMISARTAN IN THE TREATMENT OF SYSTEMIC ARTERIAL HYPERTENSION IN THE MEXICAN HEALTH SECTOR

    Nov 1, 2005, 00:00

  • PCV19 A LITERATURE REVIEW OF PATIENT-REPORTED OUTCOMES (PRO) USED IN ATRIAL FIBRILLATION

    Nov 1, 2005, 00:00

  • PDB21 COST-EFFECTIVENESS ANALYSIS OF BASAL/BOLUS THERAPY IN TYPE-1 DIABETES USING INSULIN DETEMIR + INSULIN ASPART OR HUMAN SOLUBLE INSULIN-BASED BASAL/BOLUS REGIMENS IN GERMANY

    Nov 1, 2005, 00:00

  • PHP16 ESTIMATING THE COST SAVINGS AND RATIONAL USE EFFECTS OF IMPLEMENTING AN ESSENTIAL MEDICINES LIST

    Nov 1, 2005, 00:00

  • PR2 PERCEIVED UTILITY OF HEALTH STATES INDUCED BY CHRONIC HEPATITIS B- ESTIMATES FROM UNINFECTED PERSONS IN CANADA

    Nov 1, 2005, 00:00

  • PGI4 TREATMENT OF CIRRHOSIS OF THE LIVER WITH SILYMARIN, A COST-EFFECTIVENESS ANALYSIS, BASED ON GERMAN DATA

    Nov 1, 2005, 00:00

  • UB1 MAPPING FROM DISEASE SPECIFIC MEASURES TO UTILITY- ALGORITHMS FOR ESTIMATING EQ-5D AND SF-6D VALUES FROM THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE IN PATIENTS WITH CROHN'S DISEASE

    Nov 1, 2005, 00:00

  • PCV60 COST-MINIMIZATION ANALYSIS OF TREATMENT OF MILD-TO-MODERATE HYPERTENSION IN UNITED STATES

    Nov 1, 2005, 00:00

  • PNL6 THE EPIDEMIOLOGY AND MANAGEMENT OF MIGRAINE IN THE UK

    Nov 1, 2005, 00:00

  • PMH30 FACTORS AFFECTING COST OF SCHIZOPHRENIA TREATMENT WITH ATYPICAL ANTIPSYCHOTIC AGENTS

    Nov 1, 2005, 00:00

  • PFM6 CROSS-SURVEY OF FRENCH AND PORTUGUESE GENERAL PRACTITIONERS AWARENESS AND KNOWLEDGE OF FIBROMYALGIA

    Nov 1, 2005, 00:00

  • PMC1 DEVELOPMENT OF A NEW QUESTIONNAIRE TO MEASURE SATISFACTION WITH TREATMENT WITH MEDICINES (SATMED-Q)

    Nov 1, 2005, 00:00

  • PGI3 COST-EFFECTIVENESS OF HELICOBACTER PYLORI TESTING FOR PATIENTS WITH PERSISTENT DYSPEPSIA IN THE UK

    Nov 1, 2005, 00:00

  • PRS18 DOES QUALITY OF LIFE OF COPD PATIENTS AS MEASURED BY THE GENERIC EQ-5D DIFFERENTIATE BETWEEN COPD SEVERITY STAGES?

    Nov 1, 2005, 00:00

  • PIH8 LIFESTYLE, PHYSICAL ACTIVITY AND EQ-5D HEALTH STATUS IN A OVER 65 YEARS POPULATION

    Nov 1, 2005, 00:00

  • POB1 TRENDS OF DIABETES MELLITUS PREVALENCE AND TREATMENT PATTERNS ASSOCIATED WITH OBESITY IN THE US

    Nov 1, 2005, 00:00

  • PIN15 IMPACT ON QUALITY OF LIFE OF HEALTH STATES INDUCED BY CHRONIC HEPATITIS B INFECTION- ESTIMATES FROM UNINFECTEDAND INFECTED PERSONS IN THE UK

    Nov 1, 2005, 00:00

  • PDB16 COSTS ASSOCIATED WITH GLUCOSE CONTROL IN THE NON-DIABETIC CRITICALLY ILL PATIENT

    Nov 1, 2005, 00:00

  • PCV14 THE COST OF ANTICOAGULATION MONITORING SERVICES IN THE UK NATIONAL HEALTH SERVICE

    Nov 1, 2005, 00:00

  • PCN33 COST-UTILITY ANALYSIS OF CHEMOTHERAPY IN ADVANCED OR RECURRENT GASTRIC CANCER- ORAL FLUOROPYRIMIDINETS-I VERSUS CONVENTIONAL INTRAVENOUS CHEMOTHERAPY

    Nov 1, 2005, 00:00

  • PUK26 THE IMPACT OF THE OVERACTIVE BLADDER ON QUALITY OF LIFE (SF36) AND UTILITY (EQ5D)

    Nov 1, 2005, 00:00

  • PCN8 INITIATION OF TRANSDERMAL OPIOID THERAPY IN CANCER PATIENTS WITH MODERATE OR SEVERE MALIGNANT PAIN—TREATMENT PATTERNS AND COSTS IN A GERMAN UNIVERSITY HOSPITAL

    Nov 1, 2005, 00:00

  • PAS5 IMPACT OF MONTELUKASTTHERAPY ON ASTHMA-RELATED HEALTH CARE RESOURCES USE IN MILD TO MODERATE ASTHMATIC PATIENTS WITH SEASONAL ALLERGIC RHINITIS IN SPAIN

    Nov 1, 2005, 00:00

  • PGI14 WORK ABSENTEEISM IN IRRITABLE BOWEL SYNDROME (IBS)- MEASURING DAYSVS HOURS MISSED

    Nov 1, 2005, 00:00

  • PHP14 OPPS PHARMACY HANDLING COSTS- POLICY IMPLICATIONS

    Nov 1, 2005, 00:00

  • PST3 CLOPIDOGREL VERSUS ASPIRIN IN HIGH-RISK PATIENTS WITH RECENT ISCHEMIC STROKE ORTRANSIENT ISCHEMIC ATTACK- COST-EFFECTIVENESS ANALYSIS IN ITALY

    Nov 1, 2005, 00:00

  • PCV77 COST AND OUTCOMES AFTER FIRST ACUTE MYOCARDIAL INFARCTION HOSPITAL ADMISSION- A LONGITUDINAL STUDY USING ADMINISTRATIVE DATABASES

    Nov 1, 2005, 00:00

  • PMC27 THE DEVELOPMENT OF A TREATMENT SATISFACTION QUESTIONNAIRE FOR IRON OVERLOAD (IO) PATIENTS ON CHELATION THERAPY (CT)

    Nov 1, 2005, 00:00

  • PIH6 GRUMPY OLD MEN OR HAPPY YOUNG WOMEN- THE COMPARATIVE HEALTH STATUS OF SWEDEN ANDTHE UK

    Nov 1, 2005, 00:00

  • PMH9 STIMULANT MEDICATION TREATMENT OF ATTENTION-DEFICIT/ HYPERACTIVITY DISORDER IS ASSOCIATED WITH DECREASED EMERGENCY DEPARTMENT COSTS AND UTILIZATION- POPULATION-BASED STUDY

    Nov 1, 2005, 00:00

  • UB3 A COMPARISON OF THE EQ-5D AND THE SF-6D IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

    Nov 1, 2005, 00:00

  • PAR2 METAL ON METAL (MOM) HIP RESURFACING (BIRMINGHAM HIP RESURFACING (BHR)) IN YOUNG PATIENTS WITH SEVERE HIP DAMAGE—A COST UTILITY ANALYSIS

    Nov 1, 2005, 00:00

  • PMH28 COST-EFFECTIVENESS ANALYSIS OF ZIPRASIDONE VERSUS NO TREATMENT FOR SCHIZOPHRENIA RELAPSE PREVENTION

    Nov 1, 2005, 00:00

  • PCV32 LONG-TERM COST-EFFECTIVENESS OF CLOPIDOGREL IN ACUTE CORONARY SYNDROMES BASED ON CURE AND PCI-CURE IN POLAND

    Nov 1, 2005, 00:00

  • IC3 HEALTH ECONOMIC EVALUATION OF BIVALIRUDIN IN THE MANAGEMENT OF PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN BELGIUM

    Nov 1, 2005, 00:00

  • PHP1 A COMPARISON OF FREQUENTIST AND BAYESIAN STATISTICAL APPROACHES IN COST-BENEFIT ANALYSIS

    Nov 1, 2005, 00:00

  • PCN27 ECONOMIC ANALYSIS OF BISPHOSPHONATES FROM THE PAYERS PERSPECTIVE IN BRAZIL

    Nov 1, 2005, 00:00

  • PHP45 APPRAISAL OF FIVE NEW OUT-OF-HOURS (OOH) PRIMARY CARE CENTRES IN THE PARISIAN REGION- “MAISONS MÉDICALES DE GARDE (MMG)”

    Nov 1, 2005, 00:00

  • PDB60 DEVELOPMENT AND EVALUATION OF THE ASK ADHERENCE BARRIER SURVEY IN PATIENTS WITH CHRONIC CONDITIONS

    Nov 1, 2005, 00:00

  • PSN22 SENSITIVE SKIN- IMPACT ON QUALITY OF LIFE

    Nov 1, 2005, 00:00

  • PGI15 MEDICAL RESOURCE USE AND DIRECT MEDICAL COST OF CHRONIC HEPATITIS C VIRUS INFECTION (HCVI) IN BRAZIL

    Nov 1, 2005, 00:00

  • PAR19 CRITERIA-BASED INTERPRETATION OF SF-36 IMPROVEMENTS FROM ADALIMUMAB PLUS METHOTREXATE (MTX) COMBINATION THERAPY VS. MTX ALONE IN EARLY RHEUMATOID ARTHRITIS (RA)

    Nov 1, 2005, 00:00

  • PHP15 THE CONSUMPTION OF DRUGS FINANCED BYTHE SPANISH NATIONAL HEALTH SYSTEM AND THE IMPACT OF PHARMACOVIGILANT ACTIONS

    Nov 1, 2005, 00:00

  • PMH5 A MODELLED ECONOMIC EVALUATION OF ATOMOXETINE (STRATTERA) FOR THE TREATMENT OF THREE PATIENT GROUPS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER

    Nov 1, 2005, 00:00

  • PCN44 HEALTH RELATED QUALITY OF LIFE EVALUATIONS IN PROSTATE CANCER- WHO'S BEING STUDIED?

    Nov 1, 2005, 00:00

  • PDB7 THE METABOLIC EFFECTS OF ORLISTAT AND ROSIGLITAZONE ON INSULIN ACTION IN A GROUP OF CHINESE PATIENTS AFFECTED BYTHE METABOLIC SYNDROME

    Nov 1, 2005, 00:00

  • PUK12 ASSESSING THE EFFICIENCY OF INTERSTIM® IN FECAL INCONTINENCE (Fl) IN THE SPANISH SETTING. A COST-EFFECTIVENESS SIMULATION MODEL

    Nov 1, 2005, 00:00

  • PCV2 COST-EFFECTIVENESS OF AN INTENSIVE TREATMENT WITH 80MGATORVASTATINVS 40 MG PRAVASTATIN IN ACUTE CORONARY SYNDROME- AN ECONOMIC EVALUATION BASED ON THE PROVE-IT (PRAVASTATIN ORATORVASTATIN EVALUATION AND INFECTION THERAPY)

    Nov 1, 2005, 00:00

  • PST10 THE METHODOLOGY BEHIND A PROSPECTIVE, OBSERVATIONAL STUDY OF THE ECONOMIC BURDEN OF ISCHEMIC STROKE

    Nov 1, 2005, 00:00

  • PST12 THE USE OF MULTI-CRITERIA DECISION METHODS IN HEALTH CARE.WHICH METHOD IS MOST SUITABLE FOR HEALTHY AND COGNITIVELY IMPAIRED POPULATION?

    Nov 1, 2005, 00:00

  • PCN19 AUSTRALIAN COST-EFFECTIVENESS ANALYSIS OF ANASTROZOLEVSTAMOXIFEN IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER BASED ON THE 5-YEAR COMPLETED TREATMENT ANALYSIS OF THE ATAC TRIAL

    Nov 1, 2005, 00:00

  • PHM6 ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN ADULT PATIENTS WITH HAEMOPHILIA A SWITCHED TO PROPHYLACTIC REPLACEMENT TREATMENT

    Nov 1, 2005, 00:00

  • PHP13 MULTIPLE APPRAISAL OF DRUGS IN THE UK HEALTH CARE SYSTEM

    Nov 1, 2005, 00:00

  • QL6 ADALIMUMAB REDUCES FATIGUE IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS)—6-MONTH RESULTS OF A CANADIAN AS STUDY

    Nov 1, 2005, 00:00

  • PCV36 USE OF ABCIXIMAB IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) IN FRANCE

    Nov 1, 2005, 00:00

  • PAR6 GASTROINTESTINAL (Gl) EVENTS, MEDICATION USE AND HEALTH CARE COSTS FOR NEW USERS OF CYCLOOXYGENASE (COX)-2 INHIBITORSAND NONSELECTION NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)

    Nov 1, 2005, 00:00

  • PIH1 COST-EFFECTIVENESS MODEL OF PALIVIZUMAB IN THE NETHERLANDS

    Nov 1, 2005, 00:00

  • Erratum

    Nov 1, 2005, 00:00

  • PSU1 THE SOCIETAL COST OF AUTOLOGOUS, ALLOGENEIC AND PERIOPERATIVE RBC TRANSFUSION—THE CASE OF SWEDEN

    Nov 1, 2005, 00:00

  • PUK24 BPH- CONSEQUENCES ON THE SPOUSE'S PATIENT'S SEXUALITY

    Nov 1, 2005, 00:00

  • PNL12 A RETROSPECTIVE STUDY OF DRUG TREATMENT PATTERNS AMONGST UK PRIMARY CARE PATIENTS WITH RESTLESS LEGS SYNDROME (RLS) BETWEEN I ST APRIL 2004 AND 3 I ST MARCH 2005

    Nov 1, 2005, 00:00

  • PMH23 IMPACT OF RISPERIDONE LONG-ACTING INJECTABLE ON HOSPITALIZATION AND MEDICATION USE IN PATIENTS WITH SCHIZOPHRENIA

    Nov 1, 2005, 00:00

  • PCV15 SURVEY OF CURRENT ANTICOAGULANT MONITORING SERVICES IN THE UK—A GENERAL PRACTICE PERSPECTIVE

    Nov 1, 2005, 00:00

  • PDB24 ASSESSMENT OF THE LONG-TERM COST-EFFECTIVENESS OF INSULIN ASPART + METFORMIN VERSUS HUMAN INSULIN + METFORMIN REGIMENS IN TYPE-2 DIABETES IN GERMANY BASED ON THE CLINICAL FINDINGS OF THE PHAZIT STUDY

    Nov 1, 2005, 00:00

  • PAR10 ARE THEY RELEVANT? A CRITICAL EVALUATION OF THE INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH CORE SETS FOR OSTEOARTHRITIS FROM THE PERSPECTIVE OF PATIENTS WITH KNEE OSTEOARTHRITIS IN SINGAPORE

    Nov 1, 2005, 00:00

  • PDB26 COMPARATIVE EVALUATION OF THE LONG-TERM COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 AND INSULIN GLARGINE IN A SUB-POPULATION OF POORLY CONTROLLED PATIENTS WITH TYPE-2 DIABETES RECEIVING ORAL ANTIDIABETIC AGENTS

    Nov 1, 2005, 00:00

  • PCV31 COST-EFFECTIVENESS OF CONTRAST ECHOCARDIOGRAPHY IN THE DIAGNOSIS OF CORONARY ARTERY DISEASE

    Nov 1, 2005, 00:00

  • PHM4 UK COST COMPARISON OF BUCY2 CONDITIONING IN ALLOGENEIC HSCT- ORAL VERSUS IV BUSULFAN (BUSILVEX®)

    Nov 1, 2005, 00:00

  • PCV55 EVALUATION OF COSTS RELATED TO HYPERTENSION IN PATIENTS WITH UNCONTROLLED HYPERTENSION IN POLAND

    Nov 1, 2005, 00:00

  • PHP33 USE OF PHARMACOECONOMICS FOR CREATION OF THE STATE FORMULARY IN UKRAINE

    Nov 1, 2005, 00:00

  • PAR4 OSTEOARTHRITIS-CHONDROITIN SULFATE LONG TERM UTILIZATION IS COST-SAVING

    Nov 1, 2005, 00:00

  • PEY13 COSTS AND CONSEQUENCES OF ENDOPHTHALMITIS- RESULTS FROM THE NATIONAL ENDOPHTALMITIS SURVEY

    Nov 1, 2005, 00:00

  • PCN49 HEALTH STATE DESCRIPTIONS FOR METASTATIC BREAST CANCER- A QUALITATIVE STUDY

    Nov 1, 2005, 00:00

  • Development of the Cancer Therapy Satisfaction Questionnaire- Item Generation and Content Validity Testing

    Nov 1, 2005, 00:00

  • PAR3 PRODUCTIVITY BENEFITS FROM CONTROLLED-RELEASE VS SHORT ACTING OPIOIDS FOR TREATMENT OF PERSISTENT MODERATE TO SEVERE OSTEOARTHRITIS (OA) PAIN OF THE HIP/KNEE

    Nov 1, 2005, 00:00

  • PAL3 DEVELOPMENT, PILOT TESTING, SCORING AND VALIDATION OF A MANAGEMENT TOOL FOR PATIENTS UNDERGOING SPECIFIC IMMUNO-THERAPY

    Nov 1, 2005, 00:00

  • PMC12 PHARMACOECONOMIC ASPECTS OF THE ADMINISTRATIVE REFORMS IN PHARMACEUTICAL SECTORS OF REPUBLIC HEALTH DEPARTMENTS IN MONTENEGRO

    Nov 1, 2005, 00:00

  • PIN4 COST-EFFECTIVENESS ANALYSIS OF ALTERNATIVE ANTIMICROBIAL TREATMENTS FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP)

    Nov 1, 2005, 00:00

  • PEY18 USING DISCRETE CHOICE EXPERIMENTS TO ESTIMATE QUALITY WEIGHTS WITHIN THE FRAMEWORK OF QALYS- AN APPLICATION TO GLAUCOMA

    Nov 1, 2005, 00:00

  • PUK21 INDUCED BOTHERSOMENESS IN THE ANALYSIS OF THE IPSS QUESTIONNAIRE

    Nov 1, 2005, 00:00

  • PDB48 KNOWLEDGE ABOUT INSULIN AND WILLINGNESS TO USE IT INFLUENCE GLYCEMIC CONTROL IN PATIENTS WITH TYPE-2 DIABETES MELLITUS ONLY TREATED WITH ORAL ANTIDIABETIC DRUGS—A GERMAN SURVEY

    Nov 1, 2005, 00:00

  • PMC19 HOW LONG AGO …?- ASSESSING PATIENT ADHERENCE TO SPECIFIED QUESTIONNAIRE RECALL PERIODS

    Nov 1, 2005, 00:00

  • UB4 DETERMINANTS OF HEALTH STATE UTILITY IN PATIENTS WITH PSORIATIC ARTHRITIS

    Nov 1, 2005, 00:00

  • PCN47 VALIDATION OF THE SPANISH VERSION OF THE UCLA PROSTATE CANCER INDEX- RELIABILITY AND VALIDITY OF A HEALTH-RELATED QUALITY OF LIFE MEASURE.

    Nov 1, 2005, 00:00

  • PNL11 A REVIEW OF THE ECONOMIC EVIDENCE FOR BOTULINUM TOXINS IN SPASTICITY ASSOCIATED WITH STROKE AND CEREBRAL PALSY

    Nov 1, 2005, 00:00

  • PGI7 COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) COMPARED TO LAMIVUDINE AS FIRST LINE TREATMENT OF CHRONIC HEPATITIS B (CHB) IN THE UK

    Nov 1, 2005, 00:00

  • PUK22 PATIENT SATISFACTION- INTERNATIONAL DEVELOPMENT, TRANSLATABILITY ASSESSMENT AND LINGUISTIC VALIDATION OF THE OAB-S, AN OVERACTIVE BLADDER TREATMENT SATISFACTION QUESTIONNAIRE

    Nov 1, 2005, 00:00

  • PCV25 THE ADD-ON TREATMENT WITH METOPROLOL SUCCINATE IN PATIENTS WITH CHRONIC HEART FAILURE (CHF) LEADS TO COST SAVINGS IN THE GERMAN HEALTH CARE SYSTEM—A MODEL APPROACH

    Nov 1, 2005, 00:00

  • PDB17 ECONOMIC ASSESSMENT OF ADD-ON THERAPY WITH PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) IN STATIN-TREATED PATIENTS WITH DYSLIPIDEMIA AND TYPE-2 DIABETES IN GERMANY AND SWEDEN

    Nov 1, 2005, 00:00

  • PHM7 DISEASE STATE AND QUALITY OF LIFE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES- A REVIEW OF INSTRUMENTS, DISEASE BURDEN, AND PREDICTIVE FACTORS FOR OUTCOMES

    Nov 1, 2005, 00:00

  • PUK5 ECONOMIC EVALUATION OF EVEROLIMUS WITH REDUCED-DOSE CYCLOSPORINE IN DE NOVO RENAL TRANSPLANT RECIPIENTS IN HUNGARY

    Nov 1, 2005, 00:00

  • UH3 OVERACTIVE BLADDER IN MALES- A GROWING HEALTH AND ECONOMIC BURDEN

    Nov 1, 2005, 00:00

  • HP2 PHARMACIST RESPONSE TO COMPUTER-GENERATED DRUG THERAPY ALERTS IN A LONG TERM CARE SETTING

    Nov 1, 2005, 00:00

  • PUK29 DEVELOPMENT AND VALIDATION OF A COMPREHENSIVE SYMPTOM CHECKLIST IN URINARY INCONTINENCE

    Nov 1, 2005, 00:00

  • HP6 EFFECT OF CO-PAYMENT ON COMPLIANCE TO STATINS AFTER CORONARY HEART DISEASE HOSPITALIZATION

    Nov 1, 2005, 00:00

  • Health and Economic Consequences of Sevelamer Use for Hyperphosphatemia in Patients on Hemodialysis

    Sep 1, 2005, 00:00

  • Patterns and Effectiveness of Lipid-Lowering Therapies in a Managed Care Environment

    Sep 1, 2005, 00:00

  • Health-Related Quality of Life and Other Patient-Reported Outcomes in the European Centralized Drug Regulatory Process- A Review of Guidance Documents and Performed Authorizations of Medicinal Products 1995 to 2003

    Sep 1, 2005, 00:00

  • The Routine Collation of Health Outcomes Data from Hospital Treated Subjects in the Health Outcomes Data Repository (HODaR)- Descriptive Analysis from the First 20,000 Subjects

    Sep 1, 2005, 00:00

  • Raising the Standards of Trial-Based Economic Evaluation- The Devil Is in the Detail*

    Sep 1, 2005, 00:00

  • Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials- The ISPOR RCT-CEA Task Force Report

    Sep 1, 2005, 00:00

  • Taking Clinical Trials to Task

    Sep 1, 2005, 00:00

  • Authors' Response to Comments Regarding Risperidone versus Olanzapine Markov Model

    Sep 1, 2005, 00:00

  • Functional Assessment in Migraine (FAIM) Questionnaire- Development of an Instrument Based Upon the WHO's International Classification of Functioning, Disability, and Health

    Sep 1, 2005, 00:00

  • Cost-Effectiveness of Antiplatelet Agents in Secondary Stroke Prevention- The Limits of Certainty

    Sep 1, 2005, 00:00

  • Obesity, Survival, and Hospital Costs—Findings from a Screening Project in Sweden

    Sep 1, 2005, 00:00

  • Relationship between Initial Quetiapine Dose and Effectiveness as Reflected in Subsequent Mental Health Service Use among Patients with Schizophrenia or Bipolar Disorder

    Jul 1, 2005, 00:00

  • Evidence-Based Practice to Evidence-Based Policy- Do We Really Impact on Patient Care?

    Jul 1, 2005, 00:00

  • Eliciting Women's Preferences for a Training Program in Breast Self-Examination- A Conjoint Ranking Experiment

    Jul 1, 2005, 00:00

  • Cost and Utilization Impacts of Oral Antihistamines in the California Medi-Cal Program

    Jul 1, 2005, 00:00

  • Persistence and Adherence of Medications for Chronic Overactive Bladder/Urinary Incontinence in the California Medicaid Program

    Jul 1, 2005, 00:00

  • Understanding Patient Preferences for HIV Medications Using Adaptive Conjoint Analysis- Feasibility Assessment

    Jul 1, 2005, 00:00

  • Cost Savings from Intravenous Immunoglobulin Manufactured from Chromotography/Caprylate (IGIV-C) in Persons with Primary Humoral Immunodeficiency Disorder

    Jul 1, 2005, 00:00

  • Establishing the Cost-Effectiveness of New Pharmaceuticals under Conditions of Uncertainty—When Is There Sufficient Evidence?

    Jul 1, 2005, 00:00

  • An Aging Population—Burden or Blessing?

    Jul 1, 2005, 00:00

  • Cost-Effectiveness Analysis of Rituximab Combined with CHOP for Treatment of Diffuse Large B-Cell Lymphoma

    Jul 1, 2005, 00:00

  • PDB31 FACTORS ASSOCIATED WITH HEALTH CARE COST SAVING IN PATIENTS WITH DIABETES TO THE CALIFORNIA MEDICAID POPULATIONS (MEDI-CAL)

    May 1, 2005, 00:00

  • PAL1 THE IMPACT OF THE RX-TO-OTC SWITCH OF LORATADINE AND CHANGES IN PRESCRIPTION DRUG BENEFITS ON UTILIZATION AND COST OF THERAPY

    May 1, 2005, 00:00

  • PHP35 OUTCOMES OF TECHNOLOGY APPLICATION ON PHARMACISTS JOB PERFORMANCE- THE ROLE OF PERSONAL DIGITAL ASSISTANTS

    May 1, 2005, 00:00

  • PCV35 EFFECT OF CLINICAL PHARMACIST INTERVENTION ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) OUTCOMES IN AN AMBULATORY SETTING

    May 1, 2005, 00:00

  • PMH9 ESTIMATING THE BUDGET IMPACT OF QUETIAPINE FOR THE TREATMENT OF ACUTE MANIA AMONG HOSPITALIZED PATIENTS

    May 1, 2005, 00:00

  • PCV31 DOES PLAN DESIGN AFFECT THERAPY ADHERENCE FOR CHRONIC CONDITIONS?

    May 1, 2005, 00:00

  • PIN14 OUTPATIENT COMMUNITY-ACQUIRED PNEUMONIA IN NON-ELDERLY ADULTS- UTILIZATION AND COST

    May 1, 2005, 00:00

  • PIH5 USE OF ANTIBIOTICS IN ASSOCIATION WITH DIAGNOSES OF UPPER RESPIRATORY INFECTIONS IN A LARGE ISRAELI HMO

    May 1, 2005, 00:00

  • PCV22 HEALTH AND ECONOMIC BURDEN OF POOR MEDICATION ADHERENCE IN THE UNITED STATES

    May 1, 2005, 00:00

  • PHP48 ISPOR PHARMACOECONOMICS QUALITY INDICATORS

    May 1, 2005, 00:00

  • PMH53 DIRECT HEALTH CARE COSTS OF SCHIZOPHRENIA IN THE UNITED STATES- 2002

    May 1, 2005, 00:00

  • PMH52 THE COST OF RELAPSE IN SCHIZOPHRENIA IN THE UNITED STATES

    May 1, 2005, 00:00

  • PCN26 DERIVING A PREFERENCE-BASED INDEX FROM THE MD ANDERSON SYMPTOM INVENTORY IN CANCER PATIENTS

    May 1, 2005, 00:00

  • PUK20 PATIENT SELECTION CRITERIA IMPACTS OUTCOMES IN A RETROSPECTIVE OAB STUDY

    May 1, 2005, 00:00

  • PMH38 COMPARING EXHAUSTIVE CHAID CLASSIFICATION TREE AND FORWARD STEPWISE LOGISTIC REGRESSION (LR) IN EXPLAINING THE PRESCRIBING OF ANTIDEPRESSANTS

    May 1, 2005, 00:00

  • CV5 ESTIMATING FLEXIBLE SURVIVAL FUNCTIONS FOR USE IN ECONOMIC MODELING- A CASE-STUDY USING THE CURE TRIAL

    May 1, 2005, 00:00

  • POB7 LIFETIME COSTS ASSOCIATED WITH OBESITY- A COMPUTER SIMULATION MODEL

    May 1, 2005, 00:00

  • PEN4 GENERIC AND DISEASE-SENSITIVE INSTRUMENTS SEEM TO MEASURE QUALITY OF LIFE IN A SIMILAR WAY- RESULTS OF THE EQ-5D AND QOL-AGHDA SURVEY IN THE SWEDISH POPULATION

    May 1, 2005, 00:00

  • PRS11 COMMUNITY PHARMACISTS AND TUBERCULOSIS IN THE DOTS ERA- A CROSS-SECTIONAL STUDY OF LAGOS STATE OF NIGERIA

    May 1, 2005, 00:00

  • PHP3 IMPACT OF INCREASED COPAYMENTS ON THE SWITCHING AND DISCONTINUATION RATES FOR NON FORMULARY MEDICATIONS

    May 1, 2005, 00:00

  • DB6 COMPARISON OF THE COST-EFFECTIVENESS FOR BASAL-BOLUS THERAPY OF TYPE-1 DIABETES USING INSULIN DETEMIR INSULIN ASPART OR HUMAN INSULIN-BASED REGIMENS IN THE NETHERLANDS

    May 1, 2005, 00:00

  • PAL3 WILLINGNESS TO PAY FOR INTRANASAL CORTICOSTEROID THERAPY-THE IMPORTANCE OF SENSORY ATTRIBUTES

    May 1, 2005, 00:00

  • PRS5 EVALUATION OF THE ASSOCIATION BETWEEN SEVERITY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) WITH HEALTH-RELATED UTILITY (EQ5DINDEX) AND HEALTH CARE RESOURCE USE

    May 1, 2005, 00:00

  • PDB11 EVALUATION OF THE CLINICAL OUTCOME AND FINANCIAL COSTS OF DELAYING THE ONSET OF FRANK TYPE-2 DIABETES

    May 1, 2005, 00:00

  • PMC21 DEVELOPING METHODOLOGY FOR THE TRANSLATION AND LINGUISTIC VALIDATION OF PATIENT REPORTED DIARIES

    May 1, 2005, 00:00

  • PCV43 INSURANCE COVERAGE AND AMBULATORY CARE OF HYPERTENSION FOR THE NEAR ELDERLY

    May 1, 2005, 00:00

  • PHM4 COST-EFFECTIVENESS OF TRANSFUSING BLOOD PLATELETS PREPARED WITH PATHOGEN INACTIVATION TREATMENT IN CHINA

    May 1, 2005, 00:00

  • CN3 ONCOLOGISTS COST-EFFECTIVENESS THRESHOLDS FOR NEW CANCERTHERAPIES

    May 1, 2005, 00:00

  • PCN27 INCONGRUENT DEFINITIONS OF RISK AND UNCERTAINTY AMONG CLINICAL ONCOLOGISTS AND ITS IMPLICATIONS FOR DECISION MAKING

    May 1, 2005, 00:00

  • PCV42 ADHERENCE TO ANTIHYPERTENSIVE MEDICATIONS RELATED TO COPAYMENT LEVEL

    May 1, 2005, 00:00

  • PSR5 CONTINUITY OF CARE IN STROKE PATIENTS UNDER REHABILITATION IN MEXICO

    May 1, 2005, 00:00

  • PRS4 ESTIMATING THE NUMBER OF CASES OF DIAGNOSED CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)- USE OF MEDICAL CLAIMS DATA VERSUS ALTERNATIVE METHODOLOGIES

    May 1, 2005, 00:00

  • PMH15 STUDY GAPS IN ECONOMIC EVALUATIONS OF PHARMACOTHERAPY IN BIPOLAR DISORDER

    May 1, 2005, 00:00

  • PMH25 COST AND UTILIZATION DIFFERENCES AMONG CARDIAC PATIENTS TREATED FOR DEPRESSION WITH ZOLOFT VERSUS NO PHARMACEUTICAL TREATMENT

    May 1, 2005, 00:00

  • PIHI8 DIRECT COSTS OF ERECTILE DYSFUNCTION IN A MANAGED CARE SETTING-EVIDENCE FROM A LARGE NATIONAL CLAIMS DATABASE

    May 1, 2005, 00:00

  • MC2 EVALUATION OF MEDICATION ADHERENCE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    May 1, 2005, 00:00

  • PGI1 PREVALENCE AND RISK FACTORS FOR DIARRHEA AT A LARGE TERTIARY CARE MEDICAL CENTER

    May 1, 2005, 00:00

  • PAR9 EFFECTS OF ADALIMUMAB MONOTHERAPY ON HEALTH UTILITY AND FATIGUE IN PATIENTS WITH LONG-STANDING, SEVERE RHEUMATOID ARTHRITIS (RA)

    May 1, 2005, 00:00

  • PHP32 TRENDSAND OUTCOMES ASSOCIATE WITH DTCA PRINT SUMMARY FORMATS- A FOURYEAR STUDY OF PRINT ADS

    May 1, 2005, 00:00

  • PCV34 EFFECT OF CO-PAYMENT ON THE INITIATION OF STATINS AFTER CORONARY HEART DISEASE HOSPITALIZATION

    May 1, 2005, 00:00

  • PGI12 COMPARISON OF THE MEDICATION POSSESSION RATIO ALONE AND IN COMBINATION WITH BREAKTHROUGH EVENTS FOR CLASSIFYING PATIENTS WITH ACID RELATED DISEASES

    May 1, 2005, 00:00

  • PIN3 DURATION OF ANTIBIOTIC TREATMENT IN HOSPITALIZED PATIENTS WITH COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS (CSSSI)- FINDINGS FROM A CLINICAL STUDY COMPARING TIGECYCLINE AND VANCOMYCIN/AZTREONAM

    May 1, 2005, 00:00

  • MH4 EFFECT OF SECOND-GENERATION ANTIDEPRESSANT DISCONTINUATION ON DEPRESSIVE RELAPSE IN ADULT PATIENTS WITH BIPOLAR DEPRESSION

    May 1, 2005, 00:00

  • PHPII IMPACT OF A 90-DAY RETAIL PROGRAM ON PRESCRIPTION DRUG EXPENDITURES

    May 1, 2005, 00:00

  • PEY3 REFILL COSTS AND BUDGET IMPACT OF GLAUCOMA LIPID THERAPY- A RETROSPECTIVE DATABASE ANALYSIS

    May 1, 2005, 00:00

  • PHP42 AN EXPLORATION OF PATIENT FACTORS INFLUENCING PRESCRIBERACTIVITY IN UK GENERAL PRACTICE

    May 1, 2005, 00:00

  • PCV17 CAREMARK CAREPATTERNSHEART FAILURE HOME MONITORING PROGRAM IMPROVES PARTICIPANTS HOME MONITORING COMPLIANCE

    May 1, 2005, 00:00

  • DB7 THE EFFECT OF OBESITY ADJUSTMENTS ON COST-EFFECTIVENESS MODELS OF DIABETES PREVENTION

    May 1, 2005, 00:00

  • PMH10 MENTAL HEALTH COST COMPARISON AMONG PATIENTS WITH BIPOLAR DISORDER TREATED WITH RISPERIDONE VERSUS OLANZAPINE OR QUETIAPINE IN A MANAGED CARE SETTING- A PROPENSITY-MATCHED COHORT STUDY

    May 1, 2005, 00:00

  • PGI13 USING ADVANCED SIMULATION MODELING TO EXAMINE THE IMPACT OF INCREASED RESOURCES ON PATIENT THROUGHPUT IN OUTPATIENT CARE

    May 1, 2005, 00:00

  • HPI MEDICAID DRUG SPENDING AFTER THE MEDICARE MODERNIZATION ACT- WHAT WILL BE LEFT?

    May 1, 2005, 00:00

  • PST1 ECONOMIC EVALUATION OF SIROLIMUS-ELUTING STENTS IN JAPAN

    May 1, 2005, 00:00

  • PHP30 USE OF EMERGENCY DEPARTMENTS BY HOMELESS PERSONS FOR NON-EMERGENCY CARE DURING ONEYEAR- RESOURCE USE AND COST

    May 1, 2005, 00:00

  • PCV56 EVALUATION AND COMPARISON OF DIFFERENT MODELS OF METABOLIC SYNDROME USING CONFIRMATORY FACTOR ANALYSIS

    May 1, 2005, 00:00

  • PDB36 RELIABILITY AND VALIDITY OF THE GENERAL DIABETES KNOWLEDGE TEST

    May 1, 2005, 00:00

  • PGI4 THE COST-EFFECTIVENESS OF TWO STRATEGIES FOR VACCINATING PATIENTS WITH HEPATITIS C VIRUS INFECTION AGAINST HEPATITIS A AND HEPATITIS B

    May 1, 2005, 00:00

  • CN2 VALUE-FOR-MONEY OF PEMETREXED PLUS CISPLATIN VERSUS CISPLATIN ALONE IN THE TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA

    May 1, 2005, 00:00

  • PMC15 INFLUENCE OF VARIOUS HEALTH STATUS MEASURES ON TOTAL EXPENDITURES IN THE MEPS DATASET

    May 1, 2005, 00:00

  • PDB23 EVALUATION OF THE IMPACT ON THE EQ5DINDEX (HEATH-RELATED UTILITY) OF CONVERSION TO INSULIN GLARGINE (LANTUS) FOLLOWING FAILURE ON ORAL AGENTS IN PEOPLE WITH TYPE-2 DIABETES- INTERIM ANALYSIS

    May 1, 2005, 00:00

  • PCV57 COST OF MAJOR BLEEDING FOLLOWING MAJOR ORTHOPEDIC SURGERY

    May 1, 2005, 00:00

  • PMC4 THE USE OF A LIFE ANNUITY TO MORE ACCURATELY CALCULATE MEDICAL COSTS IN A COST-EFFECTIVENESS ANALYSIS

    May 1, 2005, 00:00

  • PAL2 PATIENT PERCEPTIONS REGARDING THE USE OF OVER-THE-COUNTER CLARITIN

    May 1, 2005, 00:00

  • PUK6 A PHARMACOECONOMIC EVALUATION OF OXYBUTYNIN AND TOLTERODINE FOR THE TREATMENT OF OVERACTIVE BLADDER

    May 1, 2005, 00:00

  • PCV32 EVALUATION OF FACTORS RELATED TO DIAGNOSIS OF HYPERLIPIDEMIA- THE ROLE OF DIRECT-TO-CONSUMER ADVERTISING EXPENDITURES, HEALTH INSURANCE COVERAGE, AGE AND GENDER

    May 1, 2005, 00:00

  • PHP24 THE DETERMINANTS OF EXPENDITURES ON PHARMACEUTICALS AND OTHER MEDICAL NON-DURABLES IN OECD COUNTRIES

    May 1, 2005, 00:00

  • PHM3 DOES ANEMIA CONTRIBUTE TO LONGER LENGTH OF STAY IN PATIENTS WITH IN-HOSPITAL FALLS?

    May 1, 2005, 00:00

  • PCV16 INCREMENTAL EFFECTS OF CONCURRENT PHARMACOTHERAPEUTIC REGIMENS FOR HEART FAILURE ON HOSPITALIZATIONS AND COSTS

    May 1, 2005, 00:00

  • PAR7 SURVEY OF CURRENT TREATMENT PRACTICES OF RHEUMATOLOGISTS IN PRESCRIBING TUMOR NECROSIS FACTOR INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS

    May 1, 2005, 00:00

  • PIH23 HEALTH PREFERENCES AND WILLINGNESS TO PAYTO REDUCE EXPOSURE TO POST-MENOPAUSAL RISK FACTORS

    May 1, 2005, 00:00

  • PUK18 EVALUATION OF THE RELIABILITY AND VALIDITY OF THE INCONTINENCE QUALITY OF LIFE QUESTIONNAIRE (I-QOL) IN PATIENTS WITH DETRUSOR HYPERREFLEXIA

    May 1, 2005, 00:00

  • PDB39 DEVELOPMENT OF AN INTEGRATED DIABETES DATABASE ACROSS COMMUNITY CLINICS AND HOSPITALS

    May 1, 2005, 00:00

  • HP7 AN EVALUATION OF PHARMACEUTICAL PRICES UNDERTHE PHARMACEUTICAL FEDERAL SUPPLY SCHEDULE

    May 1, 2005, 00:00

  • PMH37 A SYSTEMATIC REVIEW OF SUICIDALITY MEASURES IN STUDIES USING SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN CHILDREN AND ADOLESCENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)

    May 1, 2005, 00:00

  • PHP43 FACTORS THAT INFLUENCE PRESCRIBING OF LOW-MOLECULAR-WEIGHT HEPARINS

    May 1, 2005, 00:00

  • PGI10 IS THE INTRODUCTION OF REFERENCE BASED PRICING FOR PATENT PROTECTED DRUGS A COST-SAVING OPTION FOR HEALTH CARE?

    May 1, 2005, 00:00

  • PCV15 POTENTIAL MEDICAL COST OFFSETS OF TREATMENT WITH ISOSRBIDE DINITRATE PLUS HYDRALAZINE IN AFRICAN AMERICANS WITH HEART FAILURE

    May 1, 2005, 00:00

  • PASI HEALTH CARE UTILIZATION, COST AND MEDICATION USE AMONG PEDIATRIC ASTHMA PATIENTS

    May 1, 2005, 00:00

  • PCV4 LONG-TERM THIENOPYRIDINE THERAPY IN ACS PATIENTS RESIDING IN THE UNITED KINGDOM

    May 1, 2005, 00:00

  • MS3 ECONOMIC EVALUATION OF CONTROLLED-RELEASE OXYCODONE (OXYCONTINTABLETS) (CRO) VERSUS OXYCODONE/ACETAMINOPHEN (PERCOCET) (OXY/APAP) FOR OSTEOARTHRITIS PAIN OF THE HIP OR KNEE

    May 1, 2005, 00:00

  • Forward

    May 1, 2005, 00:00

  • PNL19 DEVELOPMENT OF THE MULTIPLE SCLEROSIS TREATMENT SATISFACTION QUESTIONNAIRE (MSTCQ)

    May 1, 2005, 00:00

  • PMH27 COST-EFFECTIVENESS OF ESCITALOPRAM VS. VENLAFAXIN XR IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN GERMANY

    May 1, 2005, 00:00

  • PAR5 DEVELOPMENT OF BENCHMARK METHODOLOGY TO IDENTIFY GOUT PATIENTS AND GOUT ATTACKS FROM A RETROSPECTIVE DATABASE ANALYSIS

    May 1, 2005, 00:00

  • PMC14 EQUIVALENCE OF PAPER AND TOUCH SCREEN VERSIONS OF THE EQ-5D VISUAL ANALOG SCALE (EQ-VAS)

    May 1, 2005, 00:00

  • PUK10 EPOETIN ALFA AND DARBEPOETIN ALFA DOSING TRENDS IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS

    May 1, 2005, 00:00

  • PHP23 FINANCING TO MEDICINES IN MEXICO

    May 1, 2005, 00:00

  • PDB20 COMPARISON OF THE COST TO REACH A1C TARGETS IN PATIENTS WITH TYPE-2 DIABETES MELLITUS ON ORAL ANTIDIABETIC AGENTS AND EITHER BIPHASIC INSULIN ASPART 70/30 OR INSULIN GLARGINE

    May 1, 2005, 00:00

  • PMC16 LINKING DISEASE-SPECIFIC QUALITY OF LIFE (QOL) SCALES

    May 1, 2005, 00:00

  • PDB14 ECONOMIC EVALUATION OF DETEMIR-BASED BASAL/BOLUS THERAPY VERSUS NEUTRAL PROTAMINE HAGEDORN-BASED BASAL/BOLUS THERAPY FOR TYPE-1 DIABETES IN A DUTCH SETTING

    May 1, 2005, 00:00

  • PGI5 COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) COMPARED TO LAMIVUDINE FOR THE TREATMENT OF E ANTIGEN NEGATIVE CHRONIC HEPATITIS B IN THE UK

    May 1, 2005, 00:00

  • CS2 ECONOMIC IMPACT OF CARDIOVASCULAR EVENTS IN NEWLY DIAGNOSED TYPE-2 DIABETES PATIENTS

    May 1, 2005, 00:00

  • PNL26 TREATMENT SATISFACTION AND PRINCIPAL CAUSES OF TERMINATION OF DRUG TREATMENT OF PARKINSONS DISEASE IN RUSSIA

    May 1, 2005, 00:00

  • PDB38 MEASURING THE EFFECT OF THE VARIABILITY OF INSULIN USE ON HEALTH CARE COSTS IN DIABETES

    May 1, 2005, 00:00

  • PAR2 THE IMPACT OF SPECIALTY CARE ON THE UTILIZATION OF NEW DRUGS- THE CASE OF COX-2 SELECTIVE INHIBITORS

    May 1, 2005, 00:00

  • PGI14 DOES A CLINICAL STUDY REFLECT REAL-LIFE AND REAL-LIFE COSTS

    May 1, 2005, 00:00

  • PIHII THE EFFECT OF OVER-THE-COUNTER DRUG MISUSE AND THE ASSOCIATED ADES ON HRQOL IN THE ELDERLY

    May 1, 2005, 00:00

  • CS7 OVERCOMING SAMPLE-SELECTION CHALLENGES IN ECONOMIC COMPARISONS OF DRUG AND NON-DRUG THERAPY- THE CASE OF OVERACTIVE BLADDER

    May 1, 2005, 00:00

  • PGI3 THE ECONOMIC IMPLICATIONS OF SOMATROPIN [RDNA ORIGIN] MANAGEMENT IN PATIENTS WITH SHORT BOWEL SYNDROME

    May 1, 2005, 00:00

  • PMH32 APPROPRIATENESS AND VARIATION IN DRUG UTILIZATION ACROSS PATIENTS WITH DEPRESSION

    May 1, 2005, 00:00

  • PSR2 EVALUATING THE POTENTIAL COST-EFFECTIVENESS OF FUTURE ANTICOAGULANT DRUGS VS. WARFARIN IN THE PREVENTION OF STROKE AND MAJOR BLEEDS IN ATRIAL FIBRILLATION PATIENTS

    May 1, 2005, 00:00

  • PER1 EVALUATION OF AN OTITIS MEDIA EDUCATION INTERVENTION IN AN INTEGRATED DELIVERY SYSTEM

    May 1, 2005, 00:00

  • PSR8 BUILDING A LINK BETWEEN DISABILITY AFTER AN ISCHEMIC STROKE AND NEED FOR FOLLOW-UP CARE

    May 1, 2005, 00:00

  • PUK21 DEGREE OF SYMPTOM BOTHER IN URINARY INCONTINENCE

    May 1, 2005, 00:00

  • PPN2 EVALUATION OF THE DIRECT COSTS OF PURE NEUROPATHIC PAIN MANAGEMENT IN FRANCE BEFORE A FIRST CONSULTATION IN A PAIN MANAGEMENT CENTER

    May 1, 2005, 00:00

  • POS6 IMPACT OF AN OSTEOPOROSIS INTERVENTION PROGRAM OF PATIENTS WITH A FRACTURE HISTORY

    May 1, 2005, 00:00

  • PIHI0 AN EXAMINATION OF SELF-REPORTED CHRONIC CONDITIONS AND HEALTH STATUS IN THE 2001 MEDICARE HEALTH OUTCOMES SURVEY

    May 1, 2005, 00:00

  • PMH41 QUALITY OF LIFE, EMOTIONAL AND PHYSICAL SYMPTOMS IN DEPRESSION- A LITERATURE REVIEW OF SYMPTOMATOLOGY AND PATIENT REPORTED OUTCOME (PRO) INSTRUMENTS

    May 1, 2005, 00:00

  • CS5 COST OF URINARY INCONTINENCE IN GERMANY- RESULTS FROM PROSPECTIVE URINARY RESEARCH (PURE)

    May 1, 2005, 00:00

  • PCN22 ESTIMATION OF CENSORED MEDICAL COUNT DATA

    May 1, 2005, 00:00

  • PMH20 PATTERNS OF DEMENTIA/ALZHEIMER MANAGEMENT AMONG ELDERLY PATIENTS IN US AMBULATORY CARE

    May 1, 2005, 00:00

  • PCV37 PREDICTING STATIN COMPLIANCE IN NEW STARTERS WITH PHARMACY CLAIMS

    May 1, 2005, 00:00

  • PCV40 PHARMACOECONOMIC EVALUATION OF ANTIHYPERTENSIVE THERAPY IN OLABISI ONABANJO UNIVERSITY TEACHING HOSPITAL, SAGAMU, OGUN SATATE, NIGERIA

    May 1, 2005, 00:00

  • HP3 WHO WILL REQUEST A SWITCH TO NEW TREATMENT AS A RESULT OF DIRECT-TO-CONSUMERADVERTISING?

    May 1, 2005, 00:00

  • PIH7 THE PREVALENCE OF POTENTIALLY INAPPROPRIATE MEDICATION USE IN THE ELDERLY

    May 1, 2005, 00:00

  • PCV20 DECREASING HOSPITALIZATIONS FOR HEART FAILURE IN BRITISH COLUMBIA, CANADA, 1993-2001

    May 1, 2005, 00:00

  • PCV12 DATA CAPTURE VIA INTERACTIVE VOICE RESPONSE SYSTEM IN A NATIONAL STUDY OF ANTICOAGULATION MANAGEMENT

    May 1, 2005, 00:00

  • PSK1 COST-EFFECTIVENESS ANALYSIS OF AMEVIVE TM (ALEFACEPT) IN THE TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS

    May 1, 2005, 00:00

  • PUK11 ADHERENCE TO EXTENDED RELEASE TOLTERODINE VERSUS IMMEDIATE- AND EXTENDED-RELEASE OXYBUTYNIN AMONG COMMERCIALLY-INSURED PATIENTS WITH OVERACTIVE BLADDER

    May 1, 2005, 00:00

  • PIN7 AN UPDATED EVALUATION OF THE COST-EFFECTIVENESS OF VACCINATING ADOLESCENTS FOR PERTUSSIS

    May 1, 2005, 00:00

  • PNL7 DIAGNOSING PHYSICIANS, PRESCRIPTION CHOICE AND PATTERNS FOR ALZHEIMERS DISEASE IN CALIFORNIA MEDICAID PROGRAM

    May 1, 2005, 00:00

  • PDB33 PRESCRIBING TRENDS FOR COMBINATION PRODUCTS IN THE TREATMENT OF TYPE-II DIABETES

    May 1, 2005, 00:00

  • PDB17 BURDEN OF ILLNESS ASSOCIATED WITH SYMPTOMS OF DIABETIC PERIPHERAL NEUROPATHY AND DIABETIC RETINOPATHY

    May 1, 2005, 00:00

  • PAS3 A COMPARISON OF ASTHMA MEDICATION USE IN PUBLICLY VERSUS PRIVATELY INSURED CHILDREN WITH ASTHMA

    May 1, 2005, 00:00

  • PCV14 MODELING THE ECONOMIC CONSEQUENCES OF CARDIAC RESYNCHRONIZATION THERAPY IN THE UK

    May 1, 2005, 00:00

  • PSK5 COST-UTILITY ANALYSIS OF AMEVIVE TM (ALEFACEPT) IN THE TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS

    May 1, 2005, 00:00

  • POB4 RELIABLE MEASUREMENT OF OBESITY- RISK OF VASCULAR DISEASE COMPLICATIONS AS A FUNCTION OF BODY MASS INDEX AND WAIST-TO- HIP RATIO

    May 1, 2005, 00:00

  • PNL22 COST-EFFECTIVENESS OF PRAMIPEXOLE COMPARED WITH PIRIBEDIL IN EARLY PARKINSONS DISEASE PATIENTS

    May 1, 2005, 00:00

  • FM4 COX-2 INHIBITOR STEP CARE PROGRAM ON MEDICATION COSTS AND UTILIZATION- RESULTS FROM A PHARMACY BENEFIT MANAGEMENT SETTING

    May 1, 2005, 00:00

  • PDB42 ESTIMATING THE EFFECT OF SYMPTOMS OF DIABETIC PERIPHERAL NEUROPATHY AND DIABETIC RETINOPATHY ON QUALITY-OF-LIFE USING DATA FROM THE 2001-2002 NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY

    May 1, 2005, 00:00

  • PMC28 LINGUISTIC VALIDATION OF THE US SPANISH WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE, GENERAL HEALTH VERSION (WPAI-GH)

    May 1, 2005, 00:00

  • PAS6 IMPACT OF ASTHMA KNOWLEDGE ON HEALTH OUTCOMES IN PEDIATRIC PATIENTS

    May 1, 2005, 00:00

  • PST3 COST-UTILITY OF STENTING FOR SYMPTOMATIC INTRACRANIAL ATHEROSCLEROTIC DISEASE

    May 1, 2005, 00:00

  • PAR6 HEALTH CARE UTILIZATION AND DIRECT MEDICAL COSTS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN AN DEVELOPING COUNTRY

    May 1, 2005, 00:00

  • PIN23 ARE SUBJECTS ENROLLED IN CANDIDEMIA CLINICAL TRIALS REPRESENTATIVE OF MOST HOSPITALIZED PATIENTS WITH THIS DISORDER

    May 1, 2005, 00:00

  • PMC29 RECONSIDERING THE PERSPECTIVE IN ECONOMIC EVALUATION

    May 1, 2005, 00:00

  • PNL33 SLEEP COMPLAINTS AND DIAGNOSES IN THE NATIONAL AMBULATORY MEDICAL CARE SURVEY- 1997-2002

    May 1, 2005, 00:00

  • PCV5 POTENTIAL COST SAVINGS FROM ACUTE CORONARY SYNDROME TREATMENT IMPROVEMENTS

    May 1, 2005, 00:00

  • PIH6 TESTING FOR STREPTOCOCCAL INFECTIONS IN CHILDREN WITH PHARYNGITIS TREATED WITH ANTIBIOTICS INA LARGE ISRAELI HMO, 2003

    May 1, 2005, 00:00

  • CV6 RISK FACTORS AND OUTCOMES OF SURGICAL SITE INFECTIONS IN DIABETICS UNDERGOING CARDIAC SURGERY

    May 1, 2005, 00:00

  • PRS6 COMPARISON OF RESOURCE USE AND DIRECT COSTS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH AND WITHOUT COMORBID DEPRESSION IN 2001

    May 1, 2005, 00:00

  • PHP40 DEVELOPING KEY PERFORMANCE INDICATORS FORTHE AUSTRALIAN REIMBURSEMENT SYSTEM

    May 1, 2005, 00:00

  • PGI2 THE BUDGET IMPACT OF TEGASEROD ON A MANAGED CARE ORGANIZATION FORMULARY

    May 1, 2005, 00:00

  • PHP4 IMPACT OF COST ON MEDICATION COMPLIANCE IN PATIENTS WITH DIFFERENT LEVELS OF PERCEIVED BENEFITS

    May 1, 2005, 00:00

  • CV2 LIPID LEVELSAND NCEPATP-III LDL-CHOLESTEROL GOAL ATTAINMENT IN PATIENTS NEWLY-INITIATED ON ROSUVASTATIN ORATORVASTATIN

    May 1, 2005, 00:00

  • PSK3 FACTORS ASSOCIATED WITH MEDICATION USE AFFECTING HEALTH CARE COSTS IN PATIENTS WITH PSORIASIS IN THE UNITED STATES

    May 1, 2005, 00:00

  • PRS15 PREDICTING EXACERBATION EVENTS IN COPD USING ADMINISTRATIVE DATA

    May 1, 2005, 00:00

  • POS1 USING A BUDGET IMPACT MODEL TO PREDICT FIRST-YEAR USE OF A NEW OSTEOPOROSIS THERAPY

    May 1, 2005, 00:00

  • PCV28 COST-UTILITY ANALYSIS FOR STATINS IN MEXICO

    May 1, 2005, 00:00

  • PMS1 INCREMENTAL DIRECT COST OF BACK PAIN IN THE UNITED STATES IN 2001

    May 1, 2005, 00:00

  • PGI16 HEALTH RELATED QUALITY OF LIFE CHANGES IN LAMIVUDINE REFRACTORY CHRONIC HEPATITIS B (CHB PATIENTS AFTER ENTECAVIR (ETV) OR LAMIVUDINE (LAM) TREATMENTV BMS STUDY 026

    May 1, 2005, 00:00

  • PUK15 IMPACTS OF IMPLEMENTING CASE PAYMENT SYSEM TO HEMODIALYSIS OF MEDICAL AID PATIENTS ON DIALYSIS FREQUENCIES AND EXPENDITURE IN KOREA

    May 1, 2005, 00:00

  • PIN19 UTILISATION OF ANTIBIOTICS WITHIN THE SLOVAK REPUBLIC

    May 1, 2005, 00:00

  • PUK9 INTERSTITIAL CYSTITIS COSTS, TREATMENT AND COMORBIDITIES IN AN EMPLOYED POPULATION

    May 1, 2005, 00:00

  • PMH13 THE CLINICAL AND ECONOMIC OUTCOMES OF SECOND-GENERATION ANTIDEPRESSANT USE FOR BIPOLAR DISORDER

    May 1, 2005, 00:00

  • PMH42 HOSPITALIZATION AND EMERGENCY ROOM VISITS BEFORE AND AFTER TREATMENT WITH ATYPICAL ANTIPSYCHOTICS

    May 1, 2005, 00:00

  • PNL4 NURSING HOME RESIDENTS WITH ALZHEIMERS DISEASE- CHANGES IN MANAGEMENT LEVELSAND COSTS OVER A SIX YEAR PERIOD

    May 1, 2005, 00:00

  • Abstracts Index

    May 1, 2005, 00:00

  • PPN9 SEVERE PAIN IN PERSONS WHO RECEIVED HOSPICE CARE IN THE UNITED STATES (US)

    May 1, 2005, 00:00

  • PIHI9 COST-EFFECTIVENESS OF PHARMACIST PRESCRIBING AUTHORITY FOR EMERGENCY CONTRACEPTION IN BRITISH COLUMBIA

    May 1, 2005, 00:00

  • CNI COST-EFFECTIVENESS OF ONCE WEEKLY EPOETIN ALFA AND DARBEPOETIN ALFA IN TREATING CHEMOTHERAPY-INDUCED ANEMIA

    May 1, 2005, 00:00

  • PAS2 IMPACT OF ANTI-INFLAMMATORY MEDICATION ON ASTHMA COSTS IN A PEDIATRIC POPULATION

    May 1, 2005, 00:00

  • PMH39 THE USEFULNESS OF THE EQ-5D IN DIFFERENTIATING AMONG PERSONS WITH MAJOR DEPRESSIVE EPISODE AND ANXIETY

    May 1, 2005, 00:00

  • PMH63 GREATER DEPRESSIVE SYMPTOMS ARE ASSOCIATED WITH WORSE FUNCTIONAL OUTCOMES IN PATIENTS DIAGNOSED WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER

    May 1, 2005, 00:00

  • PSK2 NUMBERS-NEEDED-TO-TREAT AND ASSOCIATED COSTS OF CARE FOR TREATMENT OF MODERATE-TO-SEVERE PSORIASIS

    May 1, 2005, 00:00

  • PNL18 THE IMPACT OF MEDICARE PART D ON ECONOMIC BARRIERS TO PRESCRIPTION MEDICATIONS AMONG BENEFICIARIES WITH MULTIPLE SCLEROSIS

    May 1, 2005, 00:00

  • PHM5 RECOMBINANT HUMAN FACTOR VII USE- AN EVALUATION OF PATIENT CHARACTERISTICS AND OUTCOMES FROM AN ELECTRONIC DATABASE OF ACADEMIC HEALTH CENTERS

    May 1, 2005, 00:00

  • PHM1 EFFECTIVENESS OF EPOETIN ALFA IN REDUCING THE NUMBER OF BLOOD TRANSFUSIONS IN CRITICALLY ILL SICU PATIENTS

    May 1, 2005, 00:00

  • PGI11 LINKING SYMPTOMS SEVERITY AND DIURNALITY TO PRODUCTIVITY LOSS-A NEW CONCEPTUAL APPROACH

    May 1, 2005, 00:00

  • PHP4I A PRELIMINARY ANALYSIS OF THE RELATIONSHIP BETWEEN CONSULTATION LENGTH AND PRESCRIBER ACTIVITY IN UK GENERAL PRACTICE

    May 1, 2005, 00:00

  • PCN20 A SYSTEMATIC REVIEW OF PHYSICIAN KNOWLEDGE AND PRACTICE PATTERNS REGARDING COLORECTAL CANCER SCREENING

    May 1, 2005, 00:00

  • PEY2 CHARACTERIZATION OF THE FREQUENCY AND REASONS FOR CHANGES IN PHARMACOTHERAPY IN THE TREATMENT OF PRIMARY OPEN-ANGLE GLAUCOMA, NORMAL TENSION GLAUCOMA, AND OCULAR HYPERTENSION USING RETROSPECTIVE ANALYSIS OF THE GLASGOW ROYAL INFIRMARY ...

    May 1, 2005, 00:00

  • PRS2 AN ASSESSMENT OF DIAGNOSIS AND TREATMENT OF COPD IN PRIMARY CARE VIA AN ELECTRONIC MEDICAL RECORD DATABASE

    May 1, 2005, 00:00

  • PCN16 THE CLINICAL OUTCOMES AND COSTS OF TREATING ONCOLOGY PATIENTS FOR SEVERE SEPSIS

    May 1, 2005, 00:00

  • PHP6 SUMMARIZING DRUG USE OVER TIME- THE DRUG-O-GRAM

    May 1, 2005, 00:00

  • PIH8 INAPPROPRIATE PRESCRIBING FOR ELDERLY PATIENTS IN TWO OUTPATIENT SETTINGS

    May 1, 2005, 00:00

  • PIH4 THE QUALITY OF COMMUNITY PEDIATRICIANS PRESCRIPTIONS

    May 1, 2005, 00:00

  • Federal Sponsorship of Cost-Effectiveness and Related Research in Health Care- 1997–2001

    May 1, 2005, 00:00

  • PCV33 MONITORING OF LIPID LEVELS AND ADVERSE EVENTS AMONG TEXAS MEDICAID PATIENTS ON STATIN THERAPY

    May 1, 2005, 00:00

  • PHP9 EVALUATION OF A PLAN-PARTICIPANT MAILING PROGRAM TO ENCOURAGE USE OF MAIL-SERVICE PHARMACY AND FORMULARY DRUGS

    May 1, 2005, 00:00

  • PUK7 ESTIMATING THE COST SAVINGS DUE TO THE EFFECT OF KREMEZIN IN DELAYING THE ONSET OF RECEIVING DIALYSIS TREATMENTS AMONG PATIENTS WITH CHRONIC RENAL FAILURE

    May 1, 2005, 00:00

  • PMC1 USE OF THRESHOLDS FOR SAFETY REPORTING IN CLINICAL TRIALS

    May 1, 2005, 00:00

  • PSK8 IMPACT OF ATOPIC DERMATITIS ON THE QUALITY-OF-LIFE OF PARENTS OF CHILDREN WITH ATOPIC DERMATITIS

    May 1, 2005, 00:00

  • PRS3 ACUTE EXACERBATION OF CHRONIC BRONCHITIS (AECB) TREATMENT EFFECTIVENESS- COMPARISON OF MACROLIDES TO FLUOROQUINOLONES

    May 1, 2005, 00:00

  • PMH7 THE EFFECT OF VENLAFAXINE, PAROXETINE, AND PLACEBO ON HEALTH-RELATED WORK PRODUCTIVITY IN PANIC DISORDER PATIENTS

    May 1, 2005, 00:00

  • PUK1 SELECTED OUTCOMES IN PATIENTS WITH OVERACTIVE BLADDER COMPARED TO NON-OVERACTIVE BLADDER CONTROLS

    May 1, 2005, 00:00

  • PHP45 EVALUATING THE EFFECTIVENESS OF A PROTOCOL FOR SEDATION OF MECHANICALLYVENTILATED PATIENTS IN AN ACUTE CARE SETTING

    May 1, 2005, 00:00

  • PDB10 ECONOMIC BURDEN OF DIABETIC RETINOPATHY IN FLORIDA- A PILOT STUDY EXPLORING THE AMOUNT SPENT USING PRINCIPLE DIAGNOSES

    May 1, 2005, 00:00

  • PMH21 COSTS OF DEMENTIA AMONG COMMUNITY DWELLING PATIENTS

    May 1, 2005, 00:00

  • PHP37 EVALUATING PHARMACEUTICALS FOR REIMBURSEMENT IN KOREA

    May 1, 2005, 00:00

  • PCV58 CLINICAL AND ECONOMIC ISSUES IN THE PREVENTION OF VENOUS THROMBOEMBOLISM IN HOSPITALIZED ORTHOPEDIC PATIENTS- ENOXAPARIN VERSUS WARFARIN

    May 1, 2005, 00:00

  • HP8 FINANCIAL IMPACT OF A PRIOR-AUTHORIZATION RESTRICTION FOR PIMECROLIMUS 1 CREAM IN THE TREATMENT OF ATOPIC DERMATITIS

    May 1, 2005, 00:00

  • PAR8 ALTERNATIVE DECISION ANALYSIS MODELING IN THE ECONOMIC EVALUATION OF TUMOR NECROSIS FACTOR INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS

    May 1, 2005, 00:00

  • PEN5 ESTIMATING THE QUALITY OF LIFE DEFICIT IN ADULT GROWTH HORMONE DEFICIENCY USING AN EQ-5D CALIBRATED INDEX

    May 1, 2005, 00:00

  • PMC3 INTRODUCTION OF BIAS WHEN USING THE SMEARING RE-TRANSFORMATION METHOD IN THE PRESENCE OF POSITIVELY SKEWED ANTI-LOGGED RESIDUALS

    May 1, 2005, 00:00

  • PNL24 PATTERNS OF RESOURCE USE IN PATIENTS WITH DIFFERENT SEVERITIES OF PARKINSONS DISEASE

    May 1, 2005, 00:00

  • PRS10 PREDICTORS OF DRUG PERSISTENCY FOR ASTHMA AND COPD PATIENTS

    May 1, 2005, 00:00

  • PMH46 RELIABILITY AND VALIDITY OF THE READINESS FOR DISCHARGE QUESTIONNAIRE IN SCHIZOPHRENIA

    May 1, 2005, 00:00

  • PCV11 QUALITY OF ANTICOAGULATION CONTROL IN PATIENTS WITH ATRIAL FIBRILLATION MANAGED IN ROUTINE MEDICAL CARE IN THE UNITED STATES

    May 1, 2005, 00:00

  • PCN6 ECONOMICS OF PRIMARY SECONDARY BREAST CANCER PREVENTIVE STRATEGIES- A DECISION MODEL

    May 1, 2005, 00:00

  • DB4 HEART FAILURE RISK OFTHIAZOLIDINEDIONES INA MEDICAID MANAGED CARE POPULATION

    May 1, 2005, 00:00

  • PNL35 USING PATIENT REPORTED OUTCOMES (PROS) TO DETERMINE THE PREVALENCE OF INSOMNIA IN FOUR COUNTRIES

    May 1, 2005, 00:00

  • PDB22 LONG-TERM COST-EFFECTIVENESS OF INSULIN ASPART VERSUS SOLUBLE HUMAN INSULIN IN PATIENTS WITH TYPE 1 DIABETES IN THE UNITED KINGDOM

    May 1, 2005, 00:00

  • RSI QUALITY OF LIFE IN ASTHMA PATIENTS IS AFFECTED BY HOME TELEMANAGEMENT

    May 1, 2005, 00:00

  • PNL12 TRIPTANS FOR MIGRAINE THERAPY- A COMPARISON BASED ON NUMBER NEEDED TO TREAT AND DOSES NEEDED TO TREAT

    May 1, 2005, 00:00

  • PCV10 RACE AND GENDER COST DIFFERENCES ASSOCIATED WITH COMORBID ATRIAL FIBRILLATION IN THE HOSPITAL

    May 1, 2005, 00:00

  • PMC7 BRIDGING THE REQUIREMENT-CAPABILITY GAP BETWEEN DRUG PLAN DECISION MAKERS AND THEIR DATA ANALYSTS IN DRUG POLICY PLANNING

    May 1, 2005, 00:00

  • PMH6 DETERMINANTS OF PERMANENT NUSRING HOME ADMISSIONS AMONG ELDERLY IN THE UNITED STATES

    May 1, 2005, 00:00

  • PEY1 COMORBIDITIES AND INCIDENCE RATE OF GLAUCOMA IN THE CALIFORNIA MEDICAID POPULATION-A CASE-CONTROL STUDY

    May 1, 2005, 00:00

  • Managing Prices for Hospital Pharmaceuticals- A Successful Strategy for New Zealand?

    May 1, 2005, 00:00

  • PMC26 INTERPRETING THE MAGNITUDE OF SCORE DIFFERENCES OBJECTIVES- CONDITIONS AND OUTCOMES

    May 1, 2005, 00:00

  • PEY5 THE COST-EFFECTIVENESS OF DIFFERENT CASE-FINDING STRATEGIES FOR DETECTION AND TREATMENT OF OCULAR HYPERTENSION AND PRIMARY OPEN-ANGLE GLAUCOMA BY THE OPHTHALMOLOGIST

    May 1, 2005, 00:00

  • PAS7 DIRECT AND INDIRECT COST OF ASTHMA IN AN EMPLOYER POPULATION

    May 1, 2005, 00:00

  • EMERGENCY DEPARTMENT USE FOR ACUTE ALCOHOL INTOXICATION BY COLLEGE AGE PERSONS- TIME AND COST OF TREATMENT

    May 1, 2005, 00:00

  • PHP1 COST EFFECTIVENESS OF INTERVENTIONS TO IMPROVE ADHERENCE- WHAT IS THE QUALITY OF THE EVIDENCE?

    May 1, 2005, 00:00

  • PPN1 REDUCING MORTALITY IN PATIENTS WITH SUBSTANCE ABUSE AND CHRONIC NON-MALIGNANT PAIN THROUGH A MULTIDISCIPLINARY OPIOID RENEWAL CLINIC

    May 1, 2005, 00:00

  • POS3 COST-EFFECTIVENESS ANALYSIS OF BIPHOSPHONATES AND RALOXIFENE FOR TREATMENT OF OSTEOPOROSIS AND PREVENTION OF FRACTURES

    May 1, 2005, 00:00

  • PIHI6 UTILIZATION PATTERNS OF SIDENAFIL CITRATE IN A SENIOR MANAGED CARE POPULATION

    May 1, 2005, 00:00

  • PUK5 ECONOMIC EVALUATION OF EVEROLIMUS WITH REDUCED- DOSE CYCLOSPORINE IN DE NOVO RENAL TRANSPLANT RECIPIENTS- AN INTERNATIONAL PERSPECTIVE

    May 1, 2005, 00:00

  • PMH50 A PSYCHIATRIC HOSPITAL REVENUE AND PROFITABILITY MODEL FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA IN JAPAN

    May 1, 2005, 00:00

  • PDB19 COLLECTION OF COST DATA FOR DIABETES COMPLICATIONS IN CANADA AND AUSTRALIA

    May 1, 2005, 00:00

  • PCV50 VENOUS THROMBOEMBOLISM PROPHYLAXIS AND DRUG USE VALUE OF ENOXAPARIN IN HOSPITALIZED MYOCARDIAL INFARCTION PATIENTS

    May 1, 2005, 00:00

  • PIN25 CHRONIC RHINOSINUSITIS TREATMENT- A COMPARISON OF MOXIFLOXACIN AND LEVOFLOXACIN TREATMENT DURATION, OUTCOMES.AND CHARGES

    May 1, 2005, 00:00

  • PIH2 THE COST-EFFECTIVENESS OF EXPANDING NEWBORN SCREENING FOR INHERITED METABOLIC DISORDERS USING TANDEM MASS SPECTROMETRY

    May 1, 2005, 00:00

  • PMH11 ANTIPSYCHOTIC USE AND HOSPITALIZATION IN BIPOLAR OR MANIC PATIENTS

    May 1, 2005, 00:00

  • PDB18 ECONOMIC EVALUATION OF DRUG THERAPY AMONG DIABETES MILLITUS PATIENTS IN OLABISI ONABANJO UNIVERSITY TEACHING HOSPITAL, SAGAMU, OGUN

    May 1, 2005, 00:00

  • POB2 RECENT TRENDS AND A FUTURE FORECAST OF POPULATION BODY MASS INDEX LEVELS IN THE UNITED KINGDOM

    May 1, 2005, 00:00

  • PCN2 SURVIVAL ANALYSIS OF PAIN RELIEF PROVIDED BY DOXEPIN ORAL RINSE FOR ORAL MUCOSITIS PATIENTS

    May 1, 2005, 00:00

  • PUK3 AN ECONOMIC MODEL OF OVERACTIVE BLADDER TREATMENT PERSISTENCE-TOLTERODINE ER COMPARED TO OXYBUTYNIN ER

    May 1, 2005, 00:00

  • MHI TREATMENT COSTS OF ALZHEIMERS DISEASE IN THE CALIFORNIA MEDICAID (MEDI-CAL) PROGRAM FROM 1995 TO 2002

    May 1, 2005, 00:00

  • PRS8 COST-EFFECTIVENESS ANALYSIS OF TIOTROPIUM FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS IN JAPAN

    May 1, 2005, 00:00

  • PHP29 AN ANALYSIS OF PUBLICATION RATES OF ABSTRACTS PRESENTED AT THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICSAND OUTCOMES RESEARCH (ISPOR) INTERNATIONALAND EUROPEAN CONFERENCES DURING YEARS 2000 THROUGH 2003

    May 1, 2005, 00:00

  • PMH54 DIFFERENTIAL RISKS AND ASSOCIATED COSTS OF HOSPITALIZATION DURING ANTIPSYCHOTIC TREATMENT IN MEDICAID PATIENTS WITH SCHIZOPHRENIA

    May 1, 2005, 00:00

  • PNL6 OUTCOMES OFANTIDEPRESSANT USE IN PATIENTS WITH ALZHEIMERS DISEASE IN THE CALIFORNIA MEDICAID PROGRAM

    May 1, 2005, 00:00

  • PNL23 COST-UTILITY ANALYSIS FOR EARLY PATIENTS WITH PARKINSONS DISEASE TREATED BY DOPAMINE AGONISTS

    May 1, 2005, 00:00

  • FM3 PRESCRIPTION DRUG COPAYMENTS, MAIL ORDER SUBSTITUTION AND STOCKPILING OF MAINTENANCE MEDICATIONS

    May 1, 2005, 00:00

  • PMC5 PERSONNEL COSTS, LEARNING CURVES, AND SCALE ECONOMIES FOR TELEPHONE-BASED NURSE INTERVENTIONS

    May 1, 2005, 00:00

  • MS4 THE COST-EFFECTIVENESS OF ADDING INFLIXIMAB TO USUAL THERAPY IN THE TREATMENT OF PSORIATIC ARTHRITIS

    May 1, 2005, 00:00

  • POS4 FACTORS AFFECTING THE BONE DENSITY TEST PRESCRIBING FOR OSTEOPOROSIS IN MALE AMBULATORY PATIENTS

    May 1, 2005, 00:00

  • PHP39 DEVELOPMENT AND VALIDATION OF A CLAIMS-BASED RISK ASSESSMENT MODEL TO PREDICT PHARMACY EXPENDITURES IN A COMMERCIAL POPULATION

    May 1, 2005, 00:00

  • RS4 PRESCRIBING PATTERNS IN AMBULATORY CARE CENTERS FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    May 1, 2005, 00:00

  • PSU1 ECONOMIC BURDEN OF ILLNESS ASSOCIATED WITH CODED POSTOPERATIVE ILEUS AFTER OPEN LAPAROTOMIES

    May 1, 2005, 00:00

  • PCV21 EFFECTIVENESS OF CLINICAL PATHWAYS FOR INPATIENT HEARTH FAILURE TREATMENT- RESULTS OF A MULTICENTER CONTROLLED TRIAL

    May 1, 2005, 00:00

  • PCV49 ADVANTAGES AND LIMITATIONS OF USING A WEB-BASED SURVEY TO OBTAIN PATIENT-REPORTED OUTCOMES

    May 1, 2005, 00:00

  • PDB3 EARLY DETECTION OF CVD BY MYOCARDIAL PERFUSION IMAGING IN ASYMPTOMATIC PATIENTS WITH DIABETES

    May 1, 2005, 00:00

  • PCN7 THE COST-EFFECTIVENESS OF CAPECITABINE AS ADJUVANT ORAL CHEMOTHERAPY FOR DUKES C COLON CANCER

    May 1, 2005, 00:00

  • PMH59 THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY-E-STAR- BASELINE RESULTS FOR GERMANY, SPAIN AND AUSTRALIA

    May 1, 2005, 00:00

  • PGI8 EVALUATION OF OTC PRILOSEC STEP CARE PROGRAMS ON THE UTILIZATION AND COSTS OF PROTON PUMP INHIBITORS

    May 1, 2005, 00:00

  • PCV13 COST-EFFECTIVENESS EVALUATION OF EPLERENONE IN PATIENTS WITH HEART FAILURE FOLLOWING AMI IN GERMANY

    May 1, 2005, 00:00

  • PMH36 RASCH MODEL COMPARISON OF BECK DEPRESSION INDEX AND MOOD AND ANXIETY SYMPTOMS QUESTIONNAIRE IN MEASUREMENT OF DEPRESSION

    May 1, 2005, 00:00

  • PMH24 IMPROVEMENT OF FATIGUE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH VENLAFAXINE, SERTRALINE, OR PLACEBO

    May 1, 2005, 00:00

  • PCV2 ACUTE CORONARY SYNDROMES- ONE YEAR COSTS AND OUTCOMES

    May 1, 2005, 00:00

  • PHP36 EXAMINING THE QUALITY OF HEALTH ECONOMIC ANALYSES SUBMITTED TO THE PHARMACEUTICAL BENEFITS BOARD IN SWEDEN.-DATA FROM THE FIRST TWO YEARS

    May 1, 2005, 00:00

  • PHPI6 ADVERTISING IN RESPONSE TO NEW PRODUCT ENTRY- AN EXAMINATION OF THE STRATEGIC ROLE OF PHARMACEUTICAL ADVERTISING ON MARKET COMPETITION

    May 1, 2005, 00:00

  • PMH22 PREDICTORS OF HEALTH RELATED QUALITY OF LIFE AMONG DEMENTIA CAREGIVERS- A LONGITUDINAL EXAMINATION

    May 1, 2005, 00:00

  • PDB26 BURDEN OF NON-ADHERENCE TO ORAL ANTIDIABETICS

    May 1, 2005, 00:00

  • PHP2 THE MEDINET-PROJECT-A FEASIBILITY STUDY ON MEDICATION COMPLIANCE UNDER REAL LIFE CONDITIONS

    May 1, 2005, 00:00

  • PAR3 TESTING THE BMJ CHECKLIST AS A QUALITY ASSESSMENT TOOL FOR ECONOMIC EVALUATIONS

    May 1, 2005, 00:00

  • PGI15 VALIDATION OF EDC VERSIONS OF IBS-QOL, EQ-5D AND WPAI-IBS QUESTIONNAIRES

    May 1, 2005, 00:00

  • MC3 DOES METHOD OF CASE ASCERTAINMENT AFFECT ESTIMATES OF THE PREVALENCE AND SEVERITY OF DEMENTIA IN MEDICARE NURSING HOME RESIDENTS?

    May 1, 2005, 00:00

  • PNL15 FURTHER VALIDATION OF THE MIGRAINE TREATMENT SATISFACTION MEASURE

    May 1, 2005, 00:00

  • PCV39 PREVALENCE, AWARENESS AND CONTROL OF HYPERTENSION AMONG LATINOS IN LOS ANGELES COUNTY, CA, USA- ESTIMATES FROM THE LOS ANGELES LATINO EYE STUDY

    May 1, 2005, 00:00

  • PIH2I ADJUSTMENT FOR PUBLICATION BIAS CHANGES THE APPARENT EFFICACY OF HORMONE TREATMENT-UNADJUSTED DATA MIGHT DISTORT THE RISK-BENEFIT TRADE OFF

    May 1, 2005, 00:00

  • PMH49 ESTIMATING ANNUAL US PREVALENCE OF SCHIZOPHRENIA IN 2002

    May 1, 2005, 00:00

  • PIN17 A COMPARISON OF METHODS TO ASSESS QUALITY OF LIFE IN ECONOMIC ANALYSES OF HEPATITIS C TREATMENTS

    May 1, 2005, 00:00

  • PIHI5 IMPACT OF BENEFIT DESIGN ON PDE-5 UTILIZATION AND COSTS IN A LARGE PBM DATABASE

    May 1, 2005, 00:00

  • The Economic Value of Childhood Varicella Vaccination in France and Germany

    May 1, 2005, 00:00
  • «
  • 161 (current)
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • »